File Download

There are no files associated with this item.

  • Find it @ UNIST can give you direct access to the published full text of this article. (UNISTARs only)
Related Researcher

주진명

Joo, Jinmyoung
Laboratory for Advanced Biomaterials and Translational Medicine
Read More

Views & Downloads

Detailed Information

Cited time in webofscience Cited time in scopus
Metadata Downloads

Full metadata record

DC Field Value Language
dc.citation.endPage 7405 -
dc.citation.number 5 -
dc.citation.startPage 7395 -
dc.citation.title ACS APPLIED MATERIALS & INTERFACES -
dc.citation.volume 17 -
dc.contributor.author Jeong, Moonkyoung -
dc.contributor.author Yoon, Junyong -
dc.contributor.author Kim, Kyunghwan -
dc.contributor.author Wang, Joanna -
dc.contributor.author Koo, Yonghoe -
dc.contributor.author Sailor, Michael J. -
dc.contributor.author Joo, Jinmyoung -
dc.contributor.author Park, Ji-Ho -
dc.date.accessioned 2025-02-24T11:35:07Z -
dc.date.available 2025-02-24T11:35:07Z -
dc.date.created 2025-02-18 -
dc.date.issued 2025-02 -
dc.description.abstract Combination therapies using checkpoint inhibitors with immunostimulatory agonists have attracted great attention due to their synergistic therapeutic effects for cancer treatment. However, such combination immunotherapies require specific timing of doses to show sufficient antitumor efficacy. Sequential treatment usually requires multiple administrations of the individual drugs at specific time points, thus increasing the complexity of the drug regimen and compromising patient compliance. Here, we introduce an injectable porous silicon microparticle (pSiMP) for combination cancer immunotherapy where its multilayered nanopore structure was electrochemically programmed to achieve release of three distinct immunomodulatory drugs in the right sequence at the desired time. We find the optimal sequential treatment timeline of stimulator of interferon genes (STING) agonist, anti-OX40 antibody (aOX40), and anti-PD-1 antibody (aPD-1) for immunosuppressive tumors. We show that a single intratumoral injection of a cocktail of release-programmed pSiMPs coloaded with each antibody and a STING agonist significantly suppresses the tumor growth compared to conventional treatment involving sequential bolus injections, or an injection of pSiMPs configured to release all drugs at the same time, with no delay. With the timely release of immunomodulatory drugs, the programmable pSiMPs offer an effective treatment strategy for combination immunotherapy. -
dc.identifier.bibliographicCitation ACS APPLIED MATERIALS & INTERFACES, v.17, no.5, pp.7395 - 7405 -
dc.identifier.doi 10.1021/acsami.4c19425 -
dc.identifier.issn 1944-8244 -
dc.identifier.scopusid 2-s2.0-85217525524 -
dc.identifier.uri https://scholarworks.unist.ac.kr/handle/201301/86252 -
dc.identifier.wosid 001406185700001 -
dc.language 영어 -
dc.publisher AMER CHEMICAL SOC -
dc.title Programmable Porous Silicon Microparticles for Temporally Staged Drug Delivery in Combination Cancer Immunotherapy -
dc.type Article -
dc.description.isOpenAccess FALSE -
dc.relation.journalWebOfScienceCategory Nanoscience & Nanotechnology; Materials Science, Multidisciplinary -
dc.relation.journalResearchArea Science & Technology - Other Topics; Materials Science -
dc.type.docType Article -
dc.description.journalRegisteredClass scie -
dc.description.journalRegisteredClass scopus -
dc.subject.keywordAuthor cancer immunotherapy -
dc.subject.keywordAuthor checkpoint inhibitor -
dc.subject.keywordAuthor drug delivery -
dc.subject.keywordAuthor immunostimulatory agonist -
dc.subject.keywordAuthor poroussilicon -
dc.subject.keywordPlus SEQUENTIAL THERAPY -
dc.subject.keywordPlus SURFACE-CHEMISTRY -
dc.subject.keywordPlus PD-1 BLOCKADE -
dc.subject.keywordPlus NANOPARTICLES -
dc.subject.keywordPlus RITUXIMAB -
dc.subject.keywordPlus BELIMUMAB -
dc.subject.keywordPlus POLYMERS -
dc.subject.keywordPlus RELEASE -
dc.subject.keywordPlus ACID -

qrcode

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.